Open AccessThe effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women *
Author(s) -
Egarter Christian,
Geurts Paul,
Boschitsch Ewald,
Speiser Paul,
Huber Johannes
Publication year - 1996
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349609033337
Subject(s) - estradiol valerate , climacteric , medroxyprogesterone acetate , medicine , hormone replacement therapy (female to male) , menopause , endocrinology , estrogen , gynecology , testosterone (patch)
Background. Two sequential hormone replacement regimens, containing either estradiol valerate plus medroxyprogesterone acetate (E 2 V/MPA) or conjugated estrogens plus medrogestone (CE/MED). were compared with respect to effects on climacteric symptoms, lipid metabolism, and hemostasis. Methods. In an open, multicenter study. 51 perimenopausal women were randomized to E 2 V/ MPA and 50 to CE/MED. Assessment of climacteric complaints was performed at baseline and at months 1, 3. and 6. The effects on lipid and hemostatic variables were measured at baseline and at month 6. Quantitative data were analyzed using analysis of variance, the paired t ‐test, or the χ 2 Mantel‐Hänszel test, where appropriate. Results. Efficacy regarding treatment of climacteric symptoms was with E 2 V/MPA as good as with CE/MED. with a statistically significant reduction of most symptoms in both groups. After 6 months, total cholesterol and triglycerides had remained unchanged in both groups. High‐density lipoprotein cholesterol showed no significant change with E 2 V/MPA. whereas an increase was noted in the CE/MED group ( p <0.05). Low‐density lipoprotein cholesterol was decreased with E 2 :V/MPA ( p <0.05) and was unchanged in the CE/MED group. Hemostatic parameters showed no significant changes after 6 months, with the exception of a decreased prothrombin time with E 2 V/MPA ( p <0.05). Acceptability was excellent, expressed by the low incidence of treatment‐related drop‐outs in both groups. Conclusions. E 2 V/MPA is a one tablet per day sequential HRT regimen, which is as effective and acceptable as hormone replacement therapy with CE/MED regarding treatment of climacteric symptoms. Neither preparation had negative effects on lipid metabolism and hemostatic variables.